In 2001, Medicare made a reasonable decision. Liver transplants for a rare bile-duct cancer called intrahepatic cholangiocarcinoma produced poor results; the cancer returned in more than half of cases. The agency’s national coverage policy excluded the procedure. Then medicine moved. New treatment protocols pushed five-year survival for carefully selected patients above 50 percent. The old sentence did not move with it.
A health system that could perform the transplant was left with a grim choice: turn away Medicare patients or absorb between $800,000 and $900,000 for every procedure. It hired Applied Policy, a compact consultancy in Old Town Alexandria, Virginia, to help assemble the evidence, specialists, medical societies and patient advocates required for a formal reconsideration.
This is the company’s natural habitat. Not the clinic, exactly, and not Congress or the Centers for Medicare & Medicaid Services either. It works in the corridor connecting them - the place where a scientific breakthrough encounters a benefit category, where a hospital invoice meets a status indicator, and where an elegant therapy discovers that the billing system has never heard of it.
The real productA map through the maze
Applied Policy sells professional judgment: Medicare reimbursement and market-access strategy, CMS rule analysis, quality-program advice, legislative drafting, policy development and the choreography of stakeholder engagement. Its customers include pharmaceutical and medical-device companies, diagnostic manufacturers, hospitals, health systems, physician groups, post-acute providers, insurers, associations, patient advocates, emerging innovators and investors. They arrive when public policy has become a commercial constraint or an access problem - often both.
The five-door problem
A clinical success still has to survive three administrative doors before routine use.
The firm’s founder, James G. “Jim” Scott, has viewed that maze from unusually useful angles. He was an assistant counsel in the U.S. Senate office that turns policy ideas into statutory language and was a principal drafter of the 2003 Medicare drug law. He later advised the CMS administrator on congressional intent during implementation, then handled federal government affairs for Hoffmann-La Roche, where the abstractions became product-level questions of coding, coverage and payment. In 2009 he founded Applied Policy.
A code alone does not guarantee reimbursement.Applied Policy, explaining a 2026 HCPCS meeting
That sentence is less a disclaimer than a business thesis. FDA authorization can establish that a product is safe and effective, but Medicare still asks different questions: Is there a statutory benefit category? In which care setting is it used? Is the product paid separately or bundled into another service? Which code belongs on the claim? What evidence supports coverage? Even a favorable answer can fail if the billing office does not know what to submit.
Four case filesWhat fails first
The drugs that vanished
Hospitals were seeing denied Medicare claims for several outpatient drugs used against serious infections and cancer. Applied Policy traced the problem to erroneous CMS payment-status indicators, engaged agency staff, and helped win both a correction and retroactive reprocessing.
The $900,000 sentence
The failure was not new medicine but policy frozen in 2001. New survival evidence changed the argument, prompting a coalition and a formal request to reconsider Medicare’s exclusion of liver transplantation for iCCA.
The pump that was too new
A Midwestern Medicaid program denied early insulin-pump replacement while an old device remained under warranty. Clinical evidence and a targeted comment to the right advisory body led to case-by-case replacement for a program covering more than 700,000 people.
The antibiotic with no slot
A new inpatient antibiotic cost more than the existing hospital payment recognized. The firm secured a temporary New Technology Add-On Payment, then helped with CMS education so hospitals could actually bill for it.
Notice the pattern. The first failure is rarely “Washington” in the abstract. It is specific: the wrong indicator in a payment file, a coverage decision overtaken by evidence, a warranty condition applied too rigidly, an expensive product buried inside an old bundle. The work begins by naming the administrative object. Only then does advocacy become useful.
A method worth stealingDiagnosis before volume
Companies often respond to a reimbursement problem by turning up the volume. Applied Policy’s public case studies suggest a more disciplined sequence. It resembles debugging more than lobbying: reproduce the failure, isolate the rule responsible, find a valid pathway, and give the decision-maker enough evidence to act.
- Name the failed transaction. Start with the denied claim, blocked application or missing coverage pathway - not a broad complaint about policy.
- Locate the controlling object. Is it statute, regulation, national coverage language, a code, a status indicator, a contractor instruction or a state enrollment rule?
- Separate error from judgment. A data mistake calls for correction; outdated clinical judgment calls for new evidence; a statutory barrier may require Congress.
- Choose the smallest forum that can decide. The right CMS group, regional office, state advisory committee or formal application can beat a sprawling campaign.
- Finish the implementation. A policy win is incomplete until providers, sales teams and billing offices know what changed and how to use it.
The approach has conditions. It works best when the blockage can be identified, the proposed remedy fits existing authority, and credible clinical, economic or legal support exists. A consultant cannot conjure a benefit category Congress never created, force an agency to reopen a national decision, or guarantee that a coalition’s request will prevail. The liver-transplant case, for example, is presented as an ongoing reconsideration effort, not a completed reimbursement victory. Precision improves the odds; it does not repeal institutional limits.
Where the firm fitsSmaller than the platforms, closer to the rulebook
Applied Policy is a privately held, project-and-advisory services business, not software and not a fund. Its public materials do not list prices. The practical alternatives are larger health-policy platforms such as Avalere, specialist reimbursement firms such as ADVI, health-policy law practices, trade associations, or an internal government-affairs and market-access team. The larger firms can bring deeper data benches and global reach. In-house teams carry product memory. Law firms own questions that require legal privilege or litigation.
Large analytics, commercialization and policy teams across markets.
A small U.S. specialist team built around CMS, Congress and execution.
Maximum product context, with capacity and network limits.
Applied Policy’s proposition is narrower: a team of policy writers, lawyers, analysts, a physician and specialists with agency, legislative, clinical, coding and industry experience, close enough to Washington to convene the people who interpret the machinery. The firm also sponsors the Northern Virginia Health Policy Forum, a public series that brings CMS officials, commission leaders, researchers, journalists and industry practitioners into conversation. Its newsletter, rule summaries and podcast archive turn that listening into a visible body of work.
There is something pleasingly unfashionable about the company’s craft. It does not promise to disrupt the healthcare system. It reads the healthcare system - slowly enough to find the one field, footnote or sentence that everybody else treated as scenery. In a sector fond of calling every innovation transformative, Applied Policy’s strongest stories are more exact. A denied claim gets paid. A hospital earns the right to expand. An insulin pump can be replaced when a doctor says it should be. The paperwork changes, and then somebody’s care can change with it.